Home>Topics>Stocks>C.R. Bard

C.R. Bard

  1. All
  2. Commentary
  3. Headlines
  1. Lutonix Balloon Inflates CR Bard's Growth in Fourth Quarter


    Fri, 27 Feb 2015

    CR Bard saw strong fourth-quarter results, despite considerable foreign currency headwinds. We plan to moderately increase our fair

  2. Global Patient Temperature Management Market 2015-2019


    Fri, 20 Feb 2015

    includes a discussion of the key vendors operating in this market. Key Regions Americas APAC EMEA Key Vendors 3M Healthcare C . R . Bard Smiths Medical Stryker ZOLL Medical Other Prominent Vendors Augustine Temperature Management Belmont Instrument Charter Kontron

  3. CR Bard is Set to See Growth from its U.S. Lutonix Balloon Launch


    Thu, 23 Oct 2014

    CR Bard reported robust third-quarter results that were generally consistent with our projections. While we have not made any significant

  4. CR Bard Bolsters Narrow Moat With Technology That Appeals to Hospitals Seeking Efficiencies


    Mon, 25 Aug 2014

    We have long appreciated CR Bard 's narrow economic moat and have recently taken another look at the firm's product portfolio and general approach to navigating

  5. Boston Scientific Exceeds Our Expectations in the Second Quarter


    Thu, 24 Jul 2014

    in constant currency, propelled by urology and women's products. Moreover, the electrophysiology business purchased from CR Bard provided a boost by rounding out Boston's portfolio with complementary products. Boston held gross margin steady at 70

  6. CR Bard Sees Boost in First Quarter Thanks to Gore Royalties and Acquisitions


    Tue, 22 Apr 2014

    CR Bard reported first-quarter results that slightly exceeded our expectations, thanks to acquisitions made last year as well as royalty

  7. CR Bard Underlying Business Remains Solid in Fourth Quarter


    Fri, 31 Jan 2014

    CR Bard released solid fourth-quarter performance that generally matched our expectations, and we are leaving our fair value estimate

  8. Our Outlook for Health-Care Stocks


    Tue, 31 Dec 2013

    see China as a strategic priority and invested heavily to put down roots there. On the other hand, Edwards EW and C . R . Bard BCR have invested far less extensively in China and do not seem to view penetration of this market as a corporate priority

  9. CR Bard Reports Strong 3Q and We Plan to Raise our Fair Value Estimate


    Tue, 22 Oct 2013

    CR Bard posted strong third-quarter results that slightly exceeded our expectations. We plan to modestly raise our fair value estimate

  10. New Endo CEO Off to Good Start, but Significant Challenges Remain


    Thu, 5 Sep 2013

    increased its litigation reserve to $216 million to account for the increase, but based on recent settlements of similar cases against competitors such as C . R . Bard , it wouldn't be surprising to see the final expense exceed that amount.

« Prev1234Next »
Content Partners